CMP Pharma announced the availability of Food and Drug Administration (FDA)-approved Potassium Phosphates Injection.
Potassium Phosphates Injection is indicated:
- As a source of phosphorus in intravenous (IV) fluids to correct hypophosphatemia in patients aged ≥12 years when oral or enteral replacement is not possible, insufficient or contraindicated.
- For parenteral nutrition in adults weighing ≥45kg and pediatric patients aged ≥12 years weighing ≥40kg when oral or enteral nutrition is not possible, insufficient or contraindicated
Potassium Phosphates Injection contains phosphorus 45mmol/15mL (3mmol/mL) and potassium 71mEq/15mL (4.7mEq/mL) in 15mL single-dose vials supplied in a carton of 10. It is administered intravenously only after dilution or admixing in a larger volume of fluid.
Potassium Phosphates Injection contains aluminum that may be toxic. Exposure to aluminum is not more than 4.9mcg/kg/day when adults weighing ≥45kg are administered the recommended maximum dosage of phosphorus (45mmol/day) for parenteral nutrition or when pediatric patients ≥12 years of age weighing ≥40kg are administered the recommended maximum dosage of phosphorus (40mmol/day) for parenteral nutrition.
For more information visit cmppharma.com.